Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease

Minji Lee; Myung Jin Son; Sin-Hyoung Hong; Jae-Sung Ryu; Ji-Hyeon Min; Dong-Eon Lee; Ji Hoon Lee; Nam Doo Kim; Shi-Young Park; Darong Kim; Jeongmin Joo; Jisung Kwak; Kook Hwan Kim; Yong-Ho Lee; Byeong-Rak Keum; Hyun Seok Song; Youngae Jung; Koon Soon Kim; Gun-Hwa Kim

doi:10.1002/ctm2.1816

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (10) : e1816 DOI: 10.1002/ctm2.1816

LETTER TO THE JOURNAL

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease

Author information +

¹. Digital Omics Research Center, Korea Basic Science Institute (KBSI), Cheongju, Republic of Korea

². Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea

³. Department of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of Korea

⁴. School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea

⁵. New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, Republic of Korea

⁶. Department of Analytical Science and Technology, Graduate School of Analytical Science and Technology (GRAST), Chungnam National University, Daejeon, Republic of Korea

⁷. Department of Bio-Analytical Science, University of Science and Technology (UST), Daejeon, Republic of Korea

⁸. New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Republic of Korea

⁹. New Drug Discovery & Development, VORONOIBIO Inc., Incheon, Republic of Korea

¹⁰. Korea Mouse Metabolic Phenotyping Center, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, South Korea

¹¹. Sensor System Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

¹². Department of Chemical and Biological Engineering, Korea University, Seoul, Republic of Korea

¹³. Discovery Division, GI Innovation, Inc., Seoul, South Korea

¹⁴. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

¹⁵. Department of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea

¹⁶. Integrated Metabolomics Research Group, Metropolitan Seoul Center, Korea Basic Science Institute (KBSI), Seoul, Republic of Korea

¹⁷. Division of Endocrinology andMetabolism, Daejeon Endo Internal Medicine, Daejeon, Republic of Korea

¹⁸. Research and Development Center, CYPHARMA, Daejeon, Republic of Korea

genekgh@kbsi.re.kr

Show less

History +

PDF

Cite this article

Download citation ▾

Minji Lee, Myung Jin Son, Sin-Hyoung Hong, Jae-Sung Ryu, Ji-Hyeon Min, Dong-Eon Lee, Ji Hoon Lee, Nam Doo Kim, Shi-Young Park, Darong Kim, Jeongmin Joo, Jisung Kwak, Kook Hwan Kim, Yong-Ho Lee, Byeong-Rak Keum, Hyun Seok Song, Youngae Jung, Koon Soon Kim, Gun-Hwa Kim. Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease. Clinical and Translational Medicine, 2024, 14(10): e1816 DOI:10.1002/ctm2.1816

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. Journal of Hepatology. 2020; 73(1): 202-209.

[2]	Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; 158(7): 1999-2014. e1.

[3]	Park EC, Kim SI, Hong Y, et al. Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice. Gastroenterology. 2014; 147(4): 860-869.

[4]	Lin JH, Li H, Yasumura D, et al. IRE1 signaling affects cell fate during the unfolded protein response. Science. 2007; 318(5852): 944-949.

[5]	Zhang X, Li S, Zhou Y, et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc Natl Acad Sci U S A. 2017; 114(12): 3181-3185.

[6]	Edson KZ, Rettie AE. CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities. Curr Top Med Chem. 2013; 13(12): 1429-1440.

[7]	Li H, Toth E, Cherrington NJ. Asking the right questions with animal models: methionine-and choline-deficient model in predicting adverse drug reactions in human NASH. Toxicol Sci. 2018; 161(1): 23-33.

[8]	Gao H, Cao Y, Xia H, Zhu X, Jin Y. CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROS-induced lipid peroxidation and inflammation. Int J Mol Med. 2020; 45(4): 1121-1129.

[9]	Ryu JS, Lee M, Mun SJ, et al. Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model. J Biol Eng. 2019; 13: 69.

[10]	Mun SJ, Ryu JS, Lee MO, et al. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. J Hepatol. 2019; 71(5): 970-985.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.